Will Eli Lilly Be the First $2 Trillion Healthcare Stock? 3 Catalysts That Could Get It There.

The competition is far behind.

Lilly's obesity pill tops 7,000 prescriptions in fourth week, signals modest uptake

By Sneha S K May 8 (Reuters) - Eli Lilly's new oral weight-loss drug, Foundayo, was prescribed 7,335 times in the U.S. in the ...
BioPharma Dive

Lilly, Gilead lead pharma’s M&A boom

Deal volume in 2026 is substantially outpacing last year, and activity is being driven by interest in cancer and autoimmune ...

Eli Lilly Now Has the World's Best-Selling Drug -- But Does That Make the Stock a No-Brainer Buy?

Mounjaro generated $8.66 billion in sales in the first quarter.

Lilly’s Mounjaro overtakes Keytruda as world’s top-selling drug

Eli Lilly & Co.’s blockbuster diabetes drug Mounjaro has surpassed Merck & Co.’s cancer therapy Keytruda as the world’s ...

Eli Lilly blows past quarterly estimates, hikes outlook as Zepbound and Mounjaro sales skyrocket

Lilly hiked its full-year sales outlook by $2 billion, and also raised its adjusted profit guidance.

Novo and Lilly gain on signs weight-loss pills could expand the market

Early data from weight-loss pills are lifting shares in Novo Nordisk and Eli Lilly as investors bet that easier-to-take drugs ...

How Eli Lilly and Company Has Helped Shape Some of Medicine’s Defining Moments

From mass-producing insulin to building pharmaceutical AI “factories,” Lilly’s 150-year North Star remains the same: being in ...

Lilly pours $4.5B more into LEAP, as first facility opens in Lebanon

Eli Lilly plans to produce Foundayo, its once-daily weight loss pill in Lebanon, with an additional $4.5 billion investment.
Investor's Business Daily on MSN

Eli Lilly's retatrutide is so hot, the unlaunched weight-loss drug is already getting knocked off

Eli Lilly is just wrapping up trials of its retatrutide, but consumers already are flocking to black-market versions. Can ...